Persistent neuropathy after treatment with cisplatin and oxaliplatin

Acta Oncologica

Volumn 48, Issue 6, 2009, Pages 832-841

  Brouwers, Elke E M ^a   Huitema, Alwin D R ^a   Boogerd, Willem ^a,b   Beijnen, Jos H ^a,c   Schellens, Jan H M ^b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM MAGNESIUM); CISPLATIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; OXALIPLATIN; SODIUM THIOSULFATE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENOTYPE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NEUROLOGIC EXAMINATION; NEUROPATHY; PRIORITY JOURNAL; QUESTIONNAIRE; TESTIS CARCINOMA; TUMOR; VIBRATION; YOLK SAC TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PILOT PROJECTS; PROGNOSIS; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; YOUNG ADULT;

EID: 70350671730     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902806609     Document Type: Article

References (41)

1. Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 1986;/40:/372-6.
2. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;/53:/5970-6.
3. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993;/ 53:/799-805.
4. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003;/63:/ 1565-77.
5. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs 1995;/6:/369-83.
6. Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;/30(4Suppl 15):/5-13.
7. Boogerd W, Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJ, van der Sande JJ. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990;/9:/255-63.
8. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;/66:/1117-23.
9. Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002;/94:/ 2434-40.
10. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P. Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol 1992;/239:/199-204.
11. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006;/56:/13-6.
12. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;/8:/ 10-6.
13. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;/10:/795-803.
14. Heydorn K, Rietz B, Krarup-Hansen A. Distribution of platinum in patients treated with cisplatin determined by radiochemical neutron activation analysis. J Trace Elem Exp Med 1998;/11:/37-43.
15. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;/85:/1219-25.
16. Postma TJ, Hoekman K, van Riel JM, Heimans JJ, Vermorken JB. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neurooncol 1999;/45:/241-6.
17. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;/5:/116.
18. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;/25:/2205-11.
19. van der Hoop RG, Vecht CJ, van der Burg ME, Elderson A, Boogerd W, Heimans JJ, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;/322:/89-94.
20. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol 1999;/10:/ 1475-83.
21. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 2005;/41:/1135-9.
22. Gerr F, Letz R. Vibrotactile threshold testing in occupational health: A review of current issues and limitations. Environ Res 1993;/60:/145-59.
23. Chong PS, Cros DP. Technology literature review: Quantitative sensory testing. Muscle Nerve 2004;/29:/734-47.
24. Goldberg JM, Lindblom U. Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psych 1979;/42:/793-803.
25. Chuang HY, Schwartz J, Tsai SY, Lee ML, Wang JD, Hu H. Vibration perception thresholds in workers with long term exposure to lead. Occup Environ Med 2000;/57:/588-94.
26. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;/28:/ 495-503.
27. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;/300(Pt 1):/271-6.
28. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997;/272:/10004-12.
29. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001;/37:/593-8.
30. Jeronimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002;/11:/445-50.
31. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;/130:/461-70.
32. Brouwers EEM, Huitema ADR, Beijnen JH, Schellens JHM. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008.
33. Bland JM, Altman DG. Statistics note: Cronbach's alpha. Br Med J 1997;/314:/572.
34. Somedic AB. Stockholm Sweden. Manual for vibrameter Type III. 1985.
35. van der Hoop RG, van der Burg ME, Bokkel Huinink WW, van Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;/66:/1697-702.
36. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;/14:/2923-32. (Pubitemid 26371450)
37. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;/54:/4313-20.
38. Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathionerelated mechanisms. Mol Pharmacol 2001;/59:/837-43.
39. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin- based chemotherapy. Clin Cancer Res 2006;/12:/ 3050-6.
40. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;/25:/708-14.
41. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neurotoxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007;/5:/70.